HOTAIR (HOX Transcript Antisense RNA)

The quantitative evidence from numerous in vitro and in vivo studies has consistently demonstrated that flavonoid lncRNA modulation leads to a significant reduction in micro vessel density, expression of VEGF, and tumor burden. Improved bioavailability with more advanced nanoformulation and enhancement in preclinical validation of flavonoid lncRNA therapeutics, despite the remaining challenges like limited clinical data and off-target effects, offer low-toxicity targeted means of reprogramming tumor angiogenesis and overcoming resistance to the current therapies.

Although current research remains exploratory, lncRNAs show significant promise as predictive biomarkers and therapeutic targets. Future personalized strategies intergrating lncRNA profiles could help overcome drug resistance and improve patient outcomes.

These findings suggested that serum HOTAIR may be a potential diagnostic biomarker and that miR-646 may be a potential indicator of disease progression in EC. However, further validation in larger patient cohorts and investigation of exosomal expression levels are necessary in order to assess the potential clinical relevance and therapeutic potential of HOTAIR and miR-646.

Machine learning-assisted PEC biosensor based on DNA-AgNCs nanowires and porous COF/TiO2 nanospheres can effectively distinguish the expressions of lncRNA HOTAIR in plasma exosomes from healthy people and cancer patients, which not only significantly enhances the sensitivity and accuracy of cancer diagnosis, but also provides a great application prospect in the early diagnosis of lncRNA-related cancer.

P=N/A, N=39, Recruiting, Saglik Bilimleri Universitesi

This review synthesizes the current evidence on the ncRNA-mediated regulatory networks that influence CRC radiosensitivity, emphasizing their potential as therapeutic targets to overcome RT resistance and improve outcomes in advanced CRC. By bridging mechanistic insights with clinical applications, this work aims to guide future research and the implementation of precision RT strategies.

Our findings suggest that these selected lncRNA-related SNPs may contribute to colorectal cancer risk in a sex- and site-specific manner. These preliminary results warrant further validation in larger, independent cohorts and functional studies.

Findings do not support clinical implementation at this stage. Priorities include harmonised EV workflows, prespecified thresholds, and prospective, multi-centre validation.

These insights into lncRNA-mediated regulatory mechanisms provide promising therapeutic targets for RCC, suggesting that modulating specific lncRNAs or their associated pathways could offer innovative strategies for treatment and prognosis. This review presents a comprehensive analysis of the biogenesis, functions, and regulatory roles of lncRNAs in RCC, emphasizing their potential as diagnostic biomarkers and therapeutic targets to improve patient outcomes.

HOTAIR knockdown induced apoptosis by a 34-40 % increase in cell death and led to G2 phase arrest, enhancing sensitivity to doxorubicin in HOTAIR-knocked down cells. Targeting HOTAIR may improve treatment outcomes by promoting apoptosis and enhancing doxorubicin sensitivity in DLBCL cells.

Thus, in this comprehensive narrative review, we map the range of candidate ncRNAs reported in the literature and discuss their predictive, diagnostic, prognostic and therapeutic value, including their potential as circulating biomarkers in CC. We also highlight, as a future perspective, how integrated profiling approaches could guide research and support the development of non-invasive strategies for diagnosis, prognostic assessment, and therapy monitoring in CC.

Despite the clear potential for ncRNAs to serve as therapeutic targets and as biomarkers in clinical management of BC, additional work is required to generate optimal delivery methods, achieve specificity, and standardize detection methods. Future studies, encompassing 'multi-omics' strategies in BC research together with enhanced computational tools, will also be warranted to fully establish ncRNA discoveries into personalized BC care, and improved treatment outcomes for patient management through precision nanomedicine and liquid biopsy platforms.